ReviewImmuno-oncology technology2024
Updates in the pathogenesis and management of immune-related enterocolitis, hepatitis and cardiovascular toxicities.
Review in Immuno-oncology technology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 10 citations in OpenAlex.
- Autoimmune Hepatitis Induced by Immune Checkpoint Inhibitors in Adults: A Systematic Review.Diagnostics (Basel, Switzerland) · 2026Review
- Immune Checkpoint Inhibitor-induced Hepatitis, an Emerging Issue in Precision Cancer Therapy Era: A Narrative Literature Review.Rambam Maimonides medical journal · 2026Review
- Case Report: Neurological immune-related adverse events with anti-PD-1 based immunotherapy in cervical cancer.Frontiers in oncology · 2026Article
- Upadacitinib for anti-TNFα refractory immune checkpoint inhibitor-induced colitis: a case report.Therapeutic advances in gastroenterology · 2026Article
- Immune checkpoint inhibitors combined with chemotherapy enhance coagulation activation and elevate venous thromboembolism risk in non-small cell lung cancer.American journal of cancer research · 2026Article
- The impact of obesity-related systemic inflammation on the efficacy, toxicity, and biomarkers of immune checkpoint inhibitors in lung cancer: from mechanisms to clinical management.Frontiers in immunology · 2026Review
- Case Report: Anti-PD-1 therapy as a catalyst for the rapid transformation of a hepatic nodule into HCC: a "soil and seed" paradox in metachronous triple primary malignancies?Frontiers in immunology · 2026Article
- Neurological immune-related adverse events with checkpoint inhibitor therapy: challenges for the neurologist.Journal of neurology, neurosurgery, and psychiatry · 2025Review
- Advancing precision medicine: Uncovering biomarkers and strategies to mitigate immune-related adverse events in immune checkpoint inhibitors therapy.Toxicology reports · 2025Article
- Hematological ratios, immune-related adverse events and mortality in patients treated with immune checkpoint inhibitors.PloS one · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune checkpoint inhibitors (ICIs) have become a cornerstone of treatment for many solid organ malignancies. Alongside increasing use, the occurrence of immune-related adverse events (irAEs) has also increased and remains a significant challenge when treating patients with ICI. The underlying pathophysiology of irAE development for many organ systems is yet to be elucidated, but may involve unmasking of latent autoimmunity, increased T-cell recognition of shared antigens on cancer and normal tissue and ICI-triggered immune dysregulation with overactivation of proinflammatory pathways and suppression of immune control pathways. Management strategies for irAEs have historically been borrowed from paradigms for conventional autoimmune conditions such as inflammatory bowel disease and autoimmune hepatitis; however, recent translational efforts have clearly demonstrated key differences in underlying immune signalling pathways. As we begin to understand these differences, we must adapt a more targeted approach to immunosuppression and exercise a more nuanced approach with the multiple biologic agents available to mitigate ICI-related toxicity without reversing the antitumour effect of ICI. In this review, we focus on three key immune-related toxicities where recent clinical and translational work has provided nuanced insights into pathogenesis and treatment strategies: enterocolitis, hepatitis and cardiovascular toxicity including myocarditis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.